Yahoo
Tokyo - Delayed Quote JPY

AnGes, Inc. (4563.T)

29.00 +1.00 (+3.57%)
At close: October 30 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 4563.T
  • Previous Close 28.00
  • Open 28.00
  • Bid --
  • Ask --
  • Day's Range 28.00 - 29.00
  • 52 Week Range 28.00 - 93.00
  • Volume 875,000
  • Avg. Volume 1,713,028
  • Market Cap (intraday) 11.566B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -9.22
  • Earnings Date Nov 6, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

www.anges.co.jp

56

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4563.T
52.46%
Nikkei 225 (^N225)
25.73%

1-Year Return

4563.T
67.05%
Nikkei 225 (^N225)
23.31%

3-Year Return

4563.T
65.88%
Nikkei 225 (^N225)
106.18%

5-Year Return

4563.T
94.64%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 203M
Earnings -1.08B
Profit Margin -533.00%

Q3

FY24

Q1

FY25

Q3

FY25

Q1

FY26

-3B
-2B
-1B
0
-2500.0%
-2000.0%
-1500.0%
-1000.0%
-500.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -79.13%

  • Return on Equity (ttm)

    -214.64%

  • Revenue (ttm)

    962M

  • Net Income Avi to Common (ttm)

    -3.87B

  • Diluted EPS (ttm)

    -9.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    281M

  • Total Debt/Equity (mrq)

    352.20%

  • Levered Free Cash Flow (ttm)

    -3.68B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: